Prexigebersen

N/A

Report date: 2024/12/12 17:10:32
NME

Base Information

Drug NamePrexigebersen
Drug Alias NameLiposomal Grb2 antisense oligonucleotideLiposomal Grb-2 antisenseL-Grb-2 antisensePrexigebersen-ABP100-1-01 +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGrowth factor receptor-bound protein 2 inhibitors
TargetsGrowth factor receptor-bound protein 2
Therapy Area/IndicationsSolid tumoursObesityMyelodysplastic Syndromes +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBio-Path IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBio-Path Holdings Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursObesityEndometrial Neoplasms +[7] 
Inactive IndicationsMyelodysplastic SyndromesLeukemia, MyeloidPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A